Quick Answer
A 2026 systematic review and meta-analysis published in Geriatric Nursing pooled 7 studies covering 434 adults aged 56 to 87 with mild cognitive impairment (MCI). Meta-analysis of 6 PSQI-reporting studies found a statistically significant improvement in sleep quality (Hedges' g = 0.75; 95% CI 0.28 to 1.23), classified as a medium-to-large effect. Heterogeneity was substantial (I2 = 77.9%). Meditation modulated the HPA axis and sympathetic nervous system, and increased alpha brain-wave activity. Evidence rated: Promising.
What the research found
A 2026 systematic review and meta-analysis published in Geriatric Nursing evaluated the effectiveness of meditation-based interventions (MBIs) on sleep quality in adults aged 55 and over with mild cognitive impairment. Seven studies were included, covering 434 participants from the United States, Egypt, China, South Korea, and Brazil, in a range of settings: community-based programmes, nursing homes, dementia care centres, cancer care centres, and long-term facilities. Around 70% of participants were women. Age ranged from 56 to 87 years.
MBIs were grouped into three categories: mindfulness-based approaches, sound or mantra-based approaches, and hybrid approaches. Six of the seven studies reported sleep quality using the Pittsburgh Sleep Quality Index (PSQI). One study reported objective actigraphy data, finding increased daytime napping but no significant changes in nocturnal sleep patterns.
The mechanism: two pathways from meditation to better sleep
The review identified two distinct but interconnected pathways through which meditation-based interventions improve sleep quality. One is physiological, operating through the stress hormone system. The other is neurological, operating through brain-wave frequency. Both converge on the same endpoint: a nervous system that is safe enough to let go.
Why this matters beyond the MCI population
The study population was adults aged 56 to 87 with mild cognitive impairment. Direct extrapolation to younger, cognitively healthy adults requires caution. But the biological mechanism the study validated operates across populations. Anyone whose nervous system remains in high-alert state at bedtime experiences the same physiological barrier to deep sleep that the MBI participants faced.
If you have ever noticed that a stressful day makes for a restless night, this meta-analysis documents why in biological terms. The mechanism is not unique to MCI or to older adults. A nervous system that is still in threat-detection mode at bedtime produces shallow, unrefreshing sleep regardless of how many hours are spent in bed.
Hiya Aidasani, Scientific Editor, Sleep Performance DigestThe practical framing Hiya offers is sound: most adults look to pharmacological interventions when lifestyle, mindfulness, and behavioural approaches can produce meaningful effects and can complement pharmacological support where it is genuinely necessary. The effect size documented here (g = 0.75) is clinically meaningful, particularly given that the population studied had pre-existing cognitive vulnerability.
A note on the evidence, from our scientific editor
Hiya Aidasani reviewed this paper for the Digest. Her assessment is that the result is directionally credible but should not be overstated. The limitations are real: small total sample (434 across 7 studies), predominantly female participants, inconsistent adherence monitoring, no follow-up data on durability, and heterogeneous control conditions (some active, some passive). Only one study used objective sleep measurement, and that one study found no significant changes in nocturnal sleep architecture.
The evidence supports the conclusion that structured mind-body practice consistently improves how people with MCI report their sleep quality. It does not establish the precise architecture changes that underlie that improvement, nor how long the effect lasts, nor whether the same magnitude of effect applies in cognitively healthy adults. The mechanism is biologically plausible and consistent with a broader evidence base. The effect size is meaningful. The limitations require honest framing.
What this means tonight
A meta-analysis of 7 studies found that meditation produced a medium-to-large improvement in sleep quality in older adults with MCI. The mechanism operates through HPA axis modulation, sympathetic calming, and the shift from beta to alpha brain-wave activity. The same biology operates in any adult who brings the nervous system load of a demanding day directly to the pillow.
The practical application is not that you need to sit for an hour in formal meditation. It is that some structured transition between the last demand of the day and the sleep window, anything that creates a genuine downshift in sympathetic activity and cortisol, consistently improves the conditions under which sleep architecture can form. The practice produces the biology. The biology enables the sleep.
L-Theanine (200mg), Tagara Root (300mg), and KSM-66 Ashwagandha (300mg)
Three Night Reboot ingredients target the same nervous-system-calming pathway this meta-analysis documented, working biochemically rather than behaviourally. L-Theanine (200mg) increases alpha brain-wave activity (8-12Hz) and reduces anxiety-driven hyperarousal, directly replicating the neurological shift the meditating participants achieved. Tagara Root (300mg) prevents GABA breakdown at the beta-3 subunit and suppresses sympathetic nervous system activity, mirroring the physiological stress-quieting the MBI protocols produced. KSM-66 Ashwagandha (300mg) is shown in clinical studies to reduce cortisol, targeting the HPA-axis modulation the researchers identified as the primary sleep mechanism. Night Reboot is a food supplement. It does not treat MCI, cognitive decline, or any medical or neurological condition.
Night Reboot: 7 clinically-dosed ingredients targeting the full sleep cycle. Zero melatonin. Launching 20 September 2026.
Join the WaitlistDoes meditation improve sleep quality?
A 2026 meta-analysis of 6 out of 7 included RCTs found that meditation-based interventions produced a statistically significant improvement in self-reported sleep quality (Hedges' g = 0.75; 95% CI 0.28 to 1.23) in adults aged 55 and over with mild cognitive impairment. Heterogeneity was substantial (I2 = 77.9%). The evidence is rated Promising due to small sample sizes, predominantly subjective outcome measures, and lack of follow-up data. The mechanism is physiologically well-established and consistent across all MBI types examined.
How does meditation improve sleep?
Meditation-based interventions improve sleep through two pathways. Physiologically, they modulate the HPA axis and reduce sympathetic nervous system arousal, lowering nighttime cortisol and creating the hormonal conditions for slow-wave sleep entry. Neurologically, they reduce high-frequency gamma brain-wave activity and increase alpha brain-wave activity (8-12Hz), shifting the brain from the alert state toward the relaxed wakefulness that precedes natural sleep onset. Psychologically, they reduce anxiety and bedtime rumination that would otherwise delay sleep entry.
What is mild cognitive impairment (MCI)?
Mild cognitive impairment is a clinical state between normal age-related cognitive changes and dementia. It involves measurable cognitive decline greater than expected for age, without significant impairment of daily functioning. Adults with MCI have elevated risk of progression to Alzheimer's disease and other dementias. Sleep disturbance is common in MCI and is itself associated with faster cognitive decline, making sleep intervention in this population both relevant and practically important.
Does this research apply to people without MCI?
The study was conducted in adults aged 56-87 with MCI, so direct extrapolation requires caution. However, the core mechanism, HPA axis modulation, sympathetic calming, and the shift from beta to alpha brain waves, operates across all populations. Any adult whose nervous system remains in high arousal at bedtime experiences the same biological barrier to deep sleep. The magnitude of benefit may differ outside this specific population, but the pathway is not age-specific or diagnosis-specific.
Night Reboot. Launching 20 September 2026.
India's first sleep performance supplement. 7 clinically-dosed ingredients. Zero melatonin. Zero dependency.
Join the Waitlist- Author et al. The effects of meditation-based interventions on sleep quality among adults aged ≥ 55 with mild cognitive impairment: A systematic review and meta-analysis. Geriatric Nursing, 2026. PMID 42574777
- Buysse DJ et al. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Research. 1989;28(2):193-213. PMID 2748771
- Nobre AC et al. L-theanine, a natural constituent in tea, and its effect on mental state. Asia Pacific Journal of Clinical Nutrition. 2008;17(S1):167-168. PMID 18296328
- Chandrasekhar K et al. A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of ashwagandha root. Indian Journal of Psychological Medicine. 2012;34(3):255-262. PMID 23439798
- Benke D et al. GABA-A receptors as in vivo substrate for the anxiolytic action of valerenic acid. Neuropharmacology. 2009;56(1):174-181. PMID 18602406
Educational content only. This article is for informational and educational purposes only. It does not constitute medical advice. Consult your healthcare provider before changing your supplement regimen.
Food supplement statement. REINCARN Night Reboot is a food supplement registered under FSSAI. It is not a medicine and is not intended to diagnose, treat, cure, or prevent any disease or medical condition, including mild cognitive impairment or dementia. For adults aged 18 and over.
KSM-66 Ashwagandha note. Night Reboot contains KSM-66 Ashwagandha (300mg per serving). Ashwagandha may interact with thyroid medications and is not recommended for individuals with thyroid conditions without prior consultation with a healthcare professional.
Publisher disclosure. Published by Zandra Life Sciences Private Limited, maker of REINCARN Night Reboot. All efficacy claims are based on published clinical studies on individual ingredients; the 7-ingredient formula as a combination has not been tested in a single clinical trial.
REINCARN and Night Reboot are trademarks of Zandra Life Sciences Private Limited. Corrections: reincarn@zandralifesciences.com